Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.60 |
| ▸ | TOP2A | P11388 | 2/20 | 0.60 |
| ▸ | CES2 | O00748 | 1/20 | 0.60 |
| ▸ | CES1 | P23141 | 1/20 | 0.60 |
| ▸ | RORC | P51449 | 9/20 | 0.58 |
| ▸ | ALB | P02768 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | NT5E | P21589 | 2/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GLI1 | P08151 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.58 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.58 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.58 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127212 | 0.87 | PTPN1 (0.60) | PTPN1TOP2ACES2CES1RORC | |
| Lupeol SCHEMBL561024 | 0.76 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1RORC | |
| Lupeol SCHEMBL10061311 | 0.76 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1RORC | |
| Lupeol SCHEMBL14067725 | 0.76 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1RORC | |
| Lupeol SCHEMBL17036708 | 0.76 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1RORC | |
| Lupeol SCHEMBL7742344 | 0.76 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1RORC | |
| Lupeol SCHEMBL148518 | 0.76 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1RORC | |
| Lupeol SCHEMBL21847985 | 0.76 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1RORC | |
| Lupeol SCHEMBL21927816 | 0.76 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1RORC | |
| Lupeol SCHEMBL18100186 | 0.76 | PTPN1 (1.00) | PTPN1TOP2ACES2CES1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100221264-A1 | Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein | PANACOS PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | claimed |
| EP-1758640-A4 | INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN | PANACOS PHARMACEUTICALS INC (US) | 2009-06-03 | — | — | EP | claimed |
| EP-1758640-A2 | INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN | Panacos Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| EP-1594435-A4 | INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN | PANACOS PHARMACEUTICALS INC (US) | 2006-12-27 | — | — | EP | claimed |
| JP-2006520756-A | — | — | 2006-09-14 | — | — | JP | claimed |
| WO-2005113059-A2 | DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN | PANACOS PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | claimed |
| EP-1594435-A2 | INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN | Salzwedel, Karl (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050015039-A1 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | V.I. TECHNOLOGIES, INC. | 2005-01-20 | — | — | US | claimed |
| US-20040265320-A1 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | V.I. TECHNOLOGIES, INC. | 2004-12-30 | — | — | US | claimed |
| WO-2004069166-A2 | INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN | PANACOS PHARMACEUTICALS, INC. (US) | 2004-08-19 | — | — | WO | claimed |
| US-8318425-B2 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | The United States of America, as represented by the Secretary, Department & Human Services (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100221264-A1 | Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein | PANACOS PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| EP-1758640-A4 | INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN | PANACOS PHARMACEUTICALS INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1758640-A4 | INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN | PANACOS PHARMACEUTICALS INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7537765-B2 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | PANACOS PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1594435-A2 | INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN | Salzwedel, Karl (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050015039-A1 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | V.I. TECHNOLOGIES, INC. | 2005-01-20 | — | — | US | disclosed |
| US-20050015039-A1 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | V.I. TECHNOLOGIES, INC. | 2005-01-20 | — | — | US | disclosed |
| US-20040265320-A1 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | V.I. TECHNOLOGIES, INC. | 2004-12-30 | — | — | US | disclosed |
| WO-2004069166-A2 | INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN | PANACOS PHARMACEUTICALS, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040265320-A1 | Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein | SP1, CPSF1, BET1 | PTPN1 4095/4885TOP2A 2519/4885CES2 3154/4885 |
| US-20100221264-A1 | Inhibition of HIV-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein | SP1, CPSF1, BET1 | PTPN1 4095/4885TOP2A 2519/4885CES2 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.